Cargando…
Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high spe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445332/ https://www.ncbi.nlm.nih.gov/pubmed/28545517 http://dx.doi.org/10.1186/s12931-017-0582-1 |
_version_ | 1783238865052499968 |
---|---|
author | Trapé, Jaume Sant, Francesc Franquesa, Josefina Montesinos, Jesús Arnau, Anna Sala, Maria Bernadich, Oscar Martín, Esperanza Perich, Damià Pérez, Concha Lopez, Joan Ros, Sandra Esteve, Enrique Pérez, Rafael Aligué, Jordi Gurt, Gabriel Catot, Silvia Domenech, Montserrat Bosch, Joan Badal, Josep Miquel Bonet, Mariona Molina, Rafael Ordeig, Josep |
author_facet | Trapé, Jaume Sant, Francesc Franquesa, Josefina Montesinos, Jesús Arnau, Anna Sala, Maria Bernadich, Oscar Martín, Esperanza Perich, Damià Pérez, Concha Lopez, Joan Ros, Sandra Esteve, Enrique Pérez, Rafael Aligué, Jordi Gurt, Gabriel Catot, Silvia Domenech, Montserrat Bosch, Joan Badal, Josep Miquel Bonet, Mariona Molina, Rafael Ordeig, Josep |
author_sort | Trapé, Jaume |
collection | PubMed |
description | BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions: a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers – ADA, CRP and % of polymorphonuclear cells – improves diagnostic accuracy. METHODS: We studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum. RESULTS: Establishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio. CONCLUSIONS: The best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers. |
format | Online Article Text |
id | pubmed-5445332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54453322017-05-30 Evaluation of two strategies for the interpretation of tumour markers in pleural effusions Trapé, Jaume Sant, Francesc Franquesa, Josefina Montesinos, Jesús Arnau, Anna Sala, Maria Bernadich, Oscar Martín, Esperanza Perich, Damià Pérez, Concha Lopez, Joan Ros, Sandra Esteve, Enrique Pérez, Rafael Aligué, Jordi Gurt, Gabriel Catot, Silvia Domenech, Montserrat Bosch, Joan Badal, Josep Miquel Bonet, Mariona Molina, Rafael Ordeig, Josep Respir Res Research BACKGROUND: Pleural effusions present a diagnostic challenge. Approximately 20% are associated with cancer and some 50% require invasive procedures to perform diagnosis. Determination of tumour markers may help to identify patients with malignant effusions. Two strategies are used to obtain high specificity in the differential diagnosis of malignant pleural effusions: a) high cut-off, and b) fluid/serum (F/S) ratio and low cut-off. The aim of this study is to compare these two strategies and to establish whether the identification of possible false positives using benign biomarkers – ADA, CRP and % of polymorphonuclear cells – improves diagnostic accuracy. METHODS: We studied 402 pleural effusions, 122 of them malignant. Benign biomarkers were determined in pleural fluid, and CEA, CA72-4, CA19-9 and CA15-3 in pleural fluid and serum. RESULTS: Establishing a cut-off value for each TM for a specificity of 100%, a joint sensitivity of 66.5% was obtained. With the F/S strategy and low cut-off points, sensitivity was 77% and specificity 98.2%, Subclassifying cases with negative benign biomarkers, both strategies achieved a specificity of 100%; sensitivity was 69.9% for single determination and 80.6% for F/S ratio. CONCLUSIONS: The best interpretation of TM in the differential diagnosis of malignant pleural effusions is obtained using the F/S ratio in the group with negative benign biomarkers. BioMed Central 2017-05-25 2017 /pmc/articles/PMC5445332/ /pubmed/28545517 http://dx.doi.org/10.1186/s12931-017-0582-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Trapé, Jaume Sant, Francesc Franquesa, Josefina Montesinos, Jesús Arnau, Anna Sala, Maria Bernadich, Oscar Martín, Esperanza Perich, Damià Pérez, Concha Lopez, Joan Ros, Sandra Esteve, Enrique Pérez, Rafael Aligué, Jordi Gurt, Gabriel Catot, Silvia Domenech, Montserrat Bosch, Joan Badal, Josep Miquel Bonet, Mariona Molina, Rafael Ordeig, Josep Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title | Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title_full | Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title_fullStr | Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title_full_unstemmed | Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title_short | Evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
title_sort | evaluation of two strategies for the interpretation of tumour markers in pleural effusions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445332/ https://www.ncbi.nlm.nih.gov/pubmed/28545517 http://dx.doi.org/10.1186/s12931-017-0582-1 |
work_keys_str_mv | AT trapejaume evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT santfrancesc evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT franquesajosefina evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT montesinosjesus evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT arnauanna evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT salamaria evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT bernadichoscar evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT martinesperanza evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT perichdamia evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT perezconcha evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT lopezjoan evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT rossandra evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT esteveenrique evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT perezrafael evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT aliguejordi evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT gurtgabriel evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT catotsilvia evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT domenechmontserrat evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT boschjoan evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT badaljosepmiquel evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT bonetmariona evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT molinarafael evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions AT ordeigjosep evaluationoftwostrategiesfortheinterpretationoftumourmarkersinpleuraleffusions |